Form 4: Eton Pharma CBO Reports RSU Vesting and Tax Share Sale

Eton Pharmaceuticals' Chief Business Officer, David Krempa, reported the acquisition of 5,300 restricted stock units and the disposition of 6,264 shares for tax withholding.

Summary

• David Krempa, Chief Business Officer of Eton Pharmaceuticals, Inc. (ETON), reported transactions in the company's securities.
• On December 11, 2025, Mr. Krempa acquired 5,300 Restricted Stock Units (RSUs), which vested immediately upon award. Each RSU represents a contingent right to receive one share of ETON Common Stock.
• On December 12, 2025, Mr. Krempa disposed of 6,264 shares of Common Stock at a weighted average price of $17 per share. These shares were withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of restricted stock units.
• Following these transactions, Mr. Krempa directly beneficially owns 632,180 shares of Common Stock and 638,468 derivative securities in the form of Restricted Stock Units.

Sentiment

Score: 5

Explanation: The filing reports routine insider transactions involving the vesting of restricted stock units and subsequent tax-related share disposition, which are neutral events and do not indicate a significant positive or negative shift in company prospects.

Positives

• The acquisition of 5,300 Restricted Stock Units (RSUs) indicates continued equity incentive for the Chief Business Officer, aligning management interests with shareholder value.

Negatives

• The disposition of 6,264 shares of Common Stock, while for tax withholding purposes, reduces the direct common stock holdings of the Chief Business Officer.

Risks

• No new or specific company risks are disclosed in this routine insider transaction report.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• The Reporting Person has authorized and designated the named person to file this Form 4 on their behalf for an indefinite duration.

Industry Context

This filing is a routine disclosure of insider transactions, specifically related to executive compensation. It does not provide information that allows for analysis of broader industry trends or competitive positioning.

Comparison to Industry Standards

• Not applicable as this filing details routine insider compensation transactions, not operational or financial performance that can be benchmarked against industry peers or global standards.

Related Party Transactions

• The disposition of 6,264 shares of Common Stock was executed by the Issuer (Eton Pharmaceuticals, Inc.) to satisfy applicable withholding taxes upon the vesting of restricted stock units awarded to David Krempa, an officer of the company. This is a standard compensation-related dealing between a related party (officer) and the company.

Stakeholder Impact

• Shareholders: Minimal direct impact as these are routine compensation-related transactions for an executive.
• Employees, Customers, Suppliers, Creditors: No direct or significant impact is expected from this routine insider transaction report.

Next Steps

• No specific future actions, events, or milestones are mentioned in this routine insider transaction report.

Key Dates

Recommendation

The Form 4 details routine insider transactions related to executive compensation (RSU vesting and tax withholding). These events are generally neutral and do not provide sufficient new information to alter an investment thesis based solely on this filing. A 'hold' recommendation reflects the lack of new material information to warrant a change in investment position.

Keywords

Eton Pharmaceuticals, ETON, Form 4, insider trading, restricted stock units, CBO, David Krempa, stock transactions, equity compensation